This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aapro, M. Search for Related Content PubMed PubMed Citation Articles by Aapro, M.

Granisetron: An Update on its Clinical Use in the Management of Nausea and Vomiting

Clinique de Genolier, Genolier, Switzerland

Correspondence: Matti Aapro, M.D., 1 Route du Muids, CH-1272 Genolier, Switzerland. Telephone: 41-22-3669136; Fax: 41-22-3669131; e-mail: maapro{at}genolier.net

Nausea and vomiting are typical side effects of cytotoxic therapy and some surgical procedures. These symptoms can represent a major therapeutic challenge and, if inadequately controlled by antiemetic treatment, will result in increased mortality, morbidity, and health care costs. However, the management of nausea and vomiting has improved greatly in recent years following the introduction of the 5-HT₃-receptor antagonists, known as ‘setrons.’ In light of recent developments in antiemetic care, including the approval of the first neurokinin-1-receptor antagonist aprepitant (Emend^®; Merck and Company, Inc.; West Point, PA) and a new 5-HT₃ receptor antagonist palonosetron (Aloxi^®; MGI Pharma; Minneapolis, MN), this article provides an update on the clinical experience gained with the 5-HT₃-receptor antagonist granisetron (Kytril^®; Roche Laboratories, Inc.; Nutley, NJ) for the management of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting, and also reviews its use in special patient populations. Granisetron is a potent and highly selective 5-HT₃-receptor antagonist that has little or no affinity for other receptors, a characteristic that is thought to underlie the favorable side-effect and safety profiles of this agent. Extensive clinical trial data have shown granisetron to be an effective and well-tolerated agent for the treatment of nausea and vomiting in the oncology and surgical settings. Granisetron has also been shown to be effective and well tolerated in special populations, such as patients refractory to antiemetic treatment, patients with hepatic or renal impairment, and children. Data also suggest that its safety profile and minimal potential for drug-drug interactions would make it an antiemetic agent of choice for elderly cancer patients.

Key Words. Granisetron • 5-HT₃-receptor antagonist • Antiemetic • Nausea • Vomiting

This article has been cited by other articles:

				H. A. Mowafi, S. A. Arab, S. A. Ismail, and A. Al-Ghamdi The Effects of Intravenous Granisetron on the Sensory and Motor Blockade Produced by Intrathecal Bupivacaine Anesth. Analg., April 1, 2008; 106(4): 1322 - 1325. [Abstract] [Full Text] [PDF]

				M. Balki, S. Kasodekar, S. Dhumne, and J. C. A. Carvalho Prophylactic Granisetron Does Not Prevent Postdelivery Nausea and Vomiting During Elective Cesarean Delivery Under Spinal Anesthesia Anesth. Analg., March 1, 2007; 104(3): 679 - 683. [Abstract] [Full Text] [PDF]

				P. K. Janicki, H. G. Schuler, T. M. Jarzembowski, and M. Rossi II Prevention of Postoperative Nausea and Vomiting with Granisetron and Dolasetron in Relation to CYP2D6 Genotype. Anesth. Analg., April 1, 2006; 102(4): 1127 - 1133. [Abstract] [Full Text] [PDF]